EP3055286A1 - 4-méthylsulfonyl-2-butènenitrile et son utilisation pharmaceutique - Google Patents

4-méthylsulfonyl-2-butènenitrile et son utilisation pharmaceutique

Info

Publication number
EP3055286A1
EP3055286A1 EP14852179.2A EP14852179A EP3055286A1 EP 3055286 A1 EP3055286 A1 EP 3055286A1 EP 14852179 A EP14852179 A EP 14852179A EP 3055286 A1 EP3055286 A1 EP 3055286A1
Authority
EP
European Patent Office
Prior art keywords
pain
inflammation
butenenitrile
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14852179.2A
Other languages
German (de)
English (en)
Other versions
EP3055286A4 (fr
Inventor
Joseph P. St. Laurent
Gerald S. Jones
David M. Bresse
Scott A. Goodrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olatec Therapeutics LLC
Original Assignee
Olatec Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics LLC filed Critical Olatec Therapeutics LLC
Publication of EP3055286A1 publication Critical patent/EP3055286A1/fr
Publication of EP3055286A4 publication Critical patent/EP3055286A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • the present invention relates to 4-methylsulfonyl-2-butenenitrile and a pharmaceutical composition comprising same.
  • the present invention also relates to methods of using the compound for treating inflammation or inflammatory-related disorders and pain.
  • Inflammation is a process by which microbes or tissue injury induce the release of cytokines and chemokines from various cell types producing increased blood vessel permeability, upregulation of endothelial receptors, and thus increased egress of various cells of the innate and adaptive immune system which enter surrounding tissue and grossly produce the classical picture of inflammation, i.e. redness, swelling, heat and pain.
  • Inflammation is a localized reaction of live tissue due to an injury, which may be caused by various endogenous and exogenous factors.
  • the exogenous factors include physical, chemical, and biological factors.
  • the endogenous factors include inflammatory mediators, antigens, and antibodies. Endogenous factors often develop under the influence of an exogenous damage. An inflammatory reaction is often followed by an altered structure and penetrability of the cellular membrane. Endogenous factors, such as mediators and antigens define the nature and type of an inflammatory reaction, especially its course in the zone of injury. In the case where tissue damage is limited to the creation of mediators, an acute form of inflammation develops.
  • immunologic reactions are also involved in the process, through the interaction of antigens, antibodies, and autoantigens, a long-term inflammatory process will develop.
  • Various exogenous agents for example, infection, injury, radiation, also provide the course of inflammatory process on a molecular level by damaging cellular membranes which initiate biochemical reactions.
  • pain can be divided into three types: nociceptive, neuropathic, and mix-type.
  • Nociceptive pain is the term for pain that is detected by nociceptors.
  • Nociceptors are free nerve endings that terminate just below the skin, in tendons, in joints, and in internal organs.
  • Nociceptive pain typically responds well to treatment with opioids and NSAIDs.
  • somatic pain somatic pain
  • visceral pain comes from the internal organs.
  • Deep somatic pain is initiated by stimulation of nociceptors in ligaments, tendons, bones, blood vessels, fasciae and muscles, and is dull, aching, poorly localized pain. Examples include sprains and broken bones.
  • Superficial pain is initiated by activation of nociceptors in the skin or other superficial tissue, and is sharp, well-defined and clearly located. Examples of injuries that produce superficial somatic pain include minor wounds and minor (first degree) burns.
  • Nociceptive pain is usually short in duration and ends when the damage recovers. Examples of nociceptive pain include postoperative pain, sprains, bone fractures, burns, bumps, bruises, and inflammatory nociceptive pain. Inflammatory nociceptive pain is associated with tissue damage and the resulting inflammatory process.
  • Neuropathic pain is produced by damage to the neurons in the peripheral and central nervous systems and involves sensitization of these systems. Because the underlying etiologies are usually irreversible, most of neuropathic pain are chronic pain. Most people describe neuropathic pain as shooting, burning, tingling, lancinating, electric shock qualities, numbness, and persistent allodynia. The nomenclature of neuropathic pain is based on the site of initiating nervous system with the etiology; for examples, central post-stroke pain, diabetes peripheral neuropathy, post-herpetic (or post-shingles) neuralgia, terminal cancer pain, phantom limb pain.
  • Mix-type pain is featured by the coexistence of both nociceptive and neuropathic pain.
  • muscle pain trigger central or peripheral neuron sensitization leading to chronic low back pain, migraine, and myofacial pain.
  • Connective tissues are subjected to a constant barrage of stress and injury. Acute or chronic impacts and the natural progression of various degenerative diseases all produce painful inflammation in joint regions, such as the neck, back, arms, hips, ankles and feet. These afflictions are common and often debilitating.
  • compositions and methods for treating inflammation, inflammatory-related disorders, and pain There is a need for a composition and a method for treating inflammation, inflammatory-related disorders, and pain.
  • the composition should be economic and easy to manufacture, and the method should be effective and have no significant side effects.
  • the present invention is directed to 4-methylsulfonyl-2-butenenitrile, or a
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 4- methylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt, or solvate thereof.
  • the compound is preferably at least 90% pure (w/w).
  • the present invention is also directed to a method for treating inflammation and pain.
  • the method comprises the step of administering 4-methylsulfonyl-2-butenenitrile, or a pharmaceutically acceptable salt thereof to a subject in need thereof.
  • the pharmaceutical composition comprising the active compound can be applied by any accepted mode of administration including topical, oral, and parenteral (such as intravenous, intramuscular, subcutaneous or rectal). Topical administration and oral administration are preferred.
  • “Pharmaceutically acceptable salts,” as used herein, are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects.
  • Pharmaceutically acceptable salt forms include various crystalline polymorphs as well as the amorphous form of the different salts.
  • the pharmaceutically acceptable salts can be formed with metal or organic counterions and include, but are not limited to, alkali metal salts such as sodium or potassium; alkaline earth metal salts such as magnesium or calcium; and ammonium or tetraalkylammonium salts, i.e., NX 4 + (wherein X is C 1-4 ).
  • Solvates are addition complexes in which the compound is combined with an acceptable co-solvent in some fixed proportion.
  • the inventors have isolated and identified 4-methylsulfonyl-2-butenenitrile.
  • the compound or its pharmaceutically acceptable salt or solvate is effective for treating inflammation, inflammatory-related disorders, and pain.
  • 4-Methylsulfonyl-2-butenenitrile has a formula weight of 145.18, and its trans structure is shown below.
  • 4-Methylsulfonyl-2-butenenitrile can be synthesized by the addition of sodium methanesulfmate to 4-bromo-2-butenenitrile in an organic solvent containing water such as aqueous ethanol.
  • the requisite 4-bromo-2-butenenitrile can be prepared by bromination of allyl cyanide to give 3,4-dibromobutanenitrile, followed by base-catalyzed elimination of HBr to introduce a double bond between C2 and C3, which is expected to be an
  • the present invention is directed to a method for preparing 4-methylsulfonyl-2- butenenitrile.
  • the method comprises a step (a) of reacting 4-bromo-2-butenenitrile with sodium methanesulfmate.
  • Any solvent or solvent mixture that is suitable for providing a homogeneous solution of the reactants is suitable.
  • a water-miscible organic solvent such as ethanol, methanol, isopropanol, acetone, tetrahydrofuran, or dioxane, containing a small amount (1-10% or 1-5%) of water is a suitable solvent for the reaction.
  • ethanol: water in a ratio of 30-40:1 is used as a solvent for the reaction.
  • the method may further comprise a step (i), before the above step (a), of preparing the requisite 4-bromo-2-butenenitrile by first reacting bromine (Br 2 ) with allyl cyanide, then adding a basic solution.
  • allyl cyanide is first brominated in organic solvents such as petroleum ether and alcohol, and then HBr is eliminated from the molecule to form a double bond by introducing at least one equivalent of, preferably about one equivalent of, an appropriate base.
  • an appropriate base that is compatible with the solvents in the reaction mixture is used.
  • a preferred base is an ethanolic solution of sodium ethoxide, which can be prepared by dissolving sodium metal in ethanol.
  • the present invention provides pharmaceutical compositions comprising one pharmaceutically acceptable carriers and an active compound of 4-methylsulfonyl-2- butenenitrile, or a pharmaceutically acceptable salt or a solvate thereof.
  • the pharmaceutical composition can include one of the cis or trans isomers, or both isomers either equimolar, or of different amounts.
  • the active compound or its pharmaceutically acceptable salt or solvate in the pharmaceutical compositions in general is in an amount of about 0.01-20%, or 0.05-20%, or 0.1-20%, or 0.2-15%, or 0.5-10%, or 1-5% (w/w) for a topical formulation; about 0.1-5% for an injectable formulation, 0.1-5% for a patch formulation, about 1-90% for a tablet formulation, and 1-100% for a capsule formulation.
  • the active compound is incorporated into any acceptable carrier, including creams, gels, lotions or other types of suspensions that can stabilize the active compound and deliver it to the affected area by topical applications.
  • the pharmaceutical composition can be in a dosage form such as tablets, capsules, granules, fine granules, powders, syrups, suppositories, injectable solutions, patches, or the like.
  • the above pharmaceutical composition can be prepared by conventional methods.
  • Pharmaceutically acceptable carriers which are inactive ingredients, can be selected by those skilled in the art using conventional criteria.
  • Pharmaceutically acceptable carriers include, but are not limited to, non-aqueous based solutions, suspensions, emulsions, microemulsions, micellar solutions, gels, and ointments.
  • the pharmaceutically acceptable carriers may also contain ingredients that include, but are not limited to, saline and aqueous electrolyte solutions; ionic and nonionic osmotic agents such as sodium chloride, potassium chloride, glycerol, and dextrose; pH adjusters and buffers such as salts of hydroxide, phosphate, citrate, acetate, borate; and trolamine; antioxidants such as salts, acids and/or bases of bisulfite, sulfite, metabisulfite, thiosulfite, ascorbic acid, acetyl cysteine, cysteine, glutathione, butylated hydroxyanisole, butylated hydroxytoluene, tocopherols, and ascorbyl palmitate; surfactants such as lecithin, phospholipids, including but not limited to phosphatidylcholine, phosphatidylethanolamine and phosphatidyl inositiol; poloxa
  • hydroxypropyl methylcellulose and their salts petroleum derivatives such as mineral oil and white petrolatum; fats such as lanolin, peanut oil, palm oil, soybean oil; mono-, di-, and triglycerides; polymers of acrylic acid such as carboxypolymethylene gel, and
  • hydrophobically modified cross-linked acrylate copolymer comprising polysaccharides such as dextrans and glycosaminoglycans such as sodium hyaluronate.
  • pharmaceutically acceptable carriers may be preserved against bacterial contamination using well-known preservatives, these include, but are not limited to, benzalkonium chloride, ethylenediammetetraacetic acid and its salts, benzethonium chloride, chlorhexidine, chlorobutanol, methylparaben, thimerosal, and phenylethyl alcohol, or may be formulated as a non-preserved formulation for either single or multiple use.
  • a tablet formulation or a capsule formulation of the active compound may contain other excipients that have no bioactivity and no reaction with the active compound.
  • Excipients of a tablet or a capsule may include fillers, binders, lubricants and glidants, disintegrators, wetting agents, and release rate modifiers. Binders promote the adhesion of particles of the formulation and are important for a tablet formulation.
  • excipients of a tablet or a capsule include, but not limited to, carboxymethylcellulose, cellulose, ethylcellulose, hydroxypropylmethylcellulose, methylcellulose, karaya gum, starch, tragacanth gum, gelatin, magnesium stearate, titanium dioxide , poly(acrylic acid), and polyvinylpyrrolidone.
  • a tablet formulation may contain inactive ingredients such as colloidal silicon dioxide, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and/or titanium dioxide.
  • a capsule formulation may contain inactive ingredients such as gelatin, magnesium stearate, and/or titanium dioxide.
  • a patch formulation of the active compound may comprise some inactive ingredients such as 1,3-butylene glycol, dihydroxyaluminum aminoacetate, disodium edetate, D- sorbitol, gelatin, kaolin, methylparaben, polysorbate 80, povidone, propylene glycol, propylparaben, sodium carboxymethylcellulose, sodium polyacrylate, tartaric acid, titanium dioxide, and purified water.
  • a patch formulation may also contain skin permeability enhancer such as lactate esters (e.g., lauryl lactate) or diethylene glycol monoethyl ether.
  • Topical formulations including the active compound can be in a form of gel, cream, lotion, liquid, emulsion, ointment, spray, solution, and suspension.
  • the inactive ingredients in the topical formulations for example include, but not limited to, lauryl lactate
  • emollient/permeation enhancer diethylene glycol monoethyl ether (emollient/permeation enhancer), DMSO (solubility enhancer), silicone elastomer (rheology/texture modifier), caprylic/capric triglyceride, (emollient), octisalate, (emollient UV filter), silicone fluid
  • emollient/diluent emollient/diluent
  • squalene emollient
  • sunflower oil emollient
  • silicone dioxide thickening agent
  • lauryl lactate (for example, at about 0.1-10%, or about 0.2-5%, or about 0.5-5%) is included in the topical gel formulation.
  • Lauryl lactate is considered safe for topical administration.
  • Lauryl lactate is qualified for human use within pharmaceutical and cosmetic products.
  • Lauryl lactate when used in a topical formulation enhances the permeability of the compound.
  • Preferably lauryl lactate is purified to achieve > 90%, preferably > 95% purity; the high purity mitigates the presence of hydrolytic and oxidative agents.
  • DMSO at 0.1 -20%, or 0.5- 10% (w/w) in the formulation provides suitable solubility of the active compound.
  • diethylene glycol monoethyl ether is included in the topical gel formulation.
  • Inflammation is a process and a state of tissue pathology resulting from activation and continuation of activity of the innate and acquired components of the immune system.
  • the arachidonic acid cascade and cytokine production and action in cell to cell interactions are critical components of immune activation and response, which lead to inflammation.
  • Arachidonic acid is a component of membrane phospholipids. After it is freed from phospholipids, arachidonic acid acts as a precursor to many of the known eicosanoids including prostaglandins and leukotrienes, which are known pro-inflammatory entities.
  • the active compound is anti-inflammatory when applied topically in the mouse ear swelling model, in which the inflammation is induced by arachidonic acid.
  • the active compound is effective in inhibiting pro-inflammatory mediators.
  • the present invention is directed to a method of treating inflammation and/or pain.
  • 4- methylsulfonyl-2-butenenitrile can be used as is, or it can be administered in the form of a pharmaceutical composition that additionally contains a pharmaceutically acceptable carrier.
  • the method comprises the steps of first identifying a subject suffering from inflammation and/or pain, and administering to the subject the active compound, in an amount effective to treat inflammation and/or pain.
  • An effective amount is the amount effective to treat a disease by ameliorating the pathological condition or reducing the symptoms of the disease.
  • the method reduces or alleviates the symptoms associated with inflammation.
  • the present invention provides a method to treat localized manifestations of inflammation characterized by acute or chronic swelling, pain, redness, increased
  • the present invention provides a method to alleviate the symptoms of pain regardless of the cause of the pain.
  • the general term "pain" treatable by the present method includes nociceptive, neuropathic, and mix -type.
  • the present invention reduces pain of varying severity, i.e. mild, moderate and severe pain; acute and chronic pain.
  • the present invention is effective in treating joint pain, muscle pain, tendon pain, burn pain, and pain caused by inflammation such as rheumatoid arthritis.
  • the present invention is useful in treating inflammation and/or pain associated in a musculoskeletal system or on the skin.
  • the highly innervated, musculoskeletal and skin systems have a high capacity for demonstration of pain.
  • the highly innervated, musculoskeletal and skin systems have a high capacity for demonstration of pain.
  • musculoskeletal system has a high capacity for tissue swelling, and the skin has a high capacity for redness, swelling, and heat.
  • the degree of tissue damage is frequently magnified out of proportion to the resulting inflammatory response.
  • merely firm stroking will cause release of the cytokines, IL-1 and TNF.
  • the present invention provides a method for treating inflammation and/or pain associated with inflammatory skeletal or muscular diseases or conditions.
  • the method comprises the steps of identifying a subject in need thereof, and administering to the subject the active compound, in an amount effective to treat inflammation and/or pain.
  • the active compound as used in this application, is intended to include 4-methylsulfonyl-2-butenenitrile and its pharmaceutically acceptable salts, isomer, or isomers thereof.
  • the skeletal or muscular diseases or conditions include musculoskeletal sprains, musculoskeletal strains, tendonopathy, peripheral radiculopathy, osteoarthritis, joint degenerative disease, polymyalgia rheumatica, juvenile arthritis, gout, ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus, costochondritis, tendonitis, bursitis, such as the common lateral epicondylitis (tennis elbow), medial epicondylitis (pitchers elbow) and trochanteric bursitis, temporomandibular joint syndrome, and fibromyalgia.
  • the present invention provides a method for treating inflammation and/or pain associated with inflammatory skin diseases such as dermatitis, psoriasis, and acne.
  • the method comprises the steps of identifying a subject in need thereof, and administering to the subject the active compound, in an amount effective to treat inflammation and/or pain.
  • Skin is highly reactive to environmental stimuli and the epidermal component of keratinocytes is a very rich source of both arachidonic acid and pro-inflammatory cytokines of IL-1 and TNF.
  • Dermatitis also called eczema
  • Dermatitis is generic inflammation of the skin. Specific types of dermatitis include atopic, contact, nummular, and photo-induced.
  • 4-Methylsulfonyl-2-butenenitrile which is effective in inhibiting arachidonic acid induced inflammation and inhibiting pro-inflammatory mediators, is effective to treat inflammation and/or pain associated with psoriasis, acne, rosacea, and dermatitis, particularly contact dermatitis, and atopic dermatitis.
  • the pharmaceutical composition of the present invention can be applied by local administration and systemic administration.
  • Local administration includes topical administration.
  • Systemic administration includes oral, parenteral (such as intravenous, intramuscular, subcutaneous or rectal), and other systemic routes of administration.
  • the active compound first reaches plasma and then distributes into target tissues.
  • Topical administration and oral administration are preferred routes of administration for the present invention.
  • Dosing of the composition can vary based on the extent of the injury and each patient's individual response.
  • plasma concentrations of the active compound delivered can vary; but are generally Ixl0 ⁇ 10 -lxl0 ⁇ 4 moles/liter, and preferably Ixl0 "8 -lxl0 ⁇ 5 moles/liter.
  • the composition is applied topically onto the affected area and rubbed into it.
  • the composition is topically applied at least 1 or 2 times a day, or 3 to 4 times per day, depending on the medical issue and the disease pathology being chronic or acute.
  • the topical composition comprises about 0.01-20%, or 0.05-20%, or 0.1-20%, or 0.2- 15%, 0.5-10, or 1-5 % (w/w) of the active compound.
  • the topical composition comprises about 1 or 5 % (w/w) of the active compound.
  • 0.2-85 mL, typically 0.2-10 mL of the topical composition is applied to the individual per dose.
  • the active compound passes through skin and is delivered to the site of discomfort.
  • the pharmaceutical composition is administrated orally to the subject.
  • the dosage for oral administration is generally 1-50, and preferably 1-10, or 1-5 mg/kg/day.
  • the active compound can be applied orally to an adult human at 100-800 mg/dosage, or 200-600 mg/dosage, 1-4 times a day, depends on the patient's condition.
  • the pharmaceutical composition is administrated subcutaneously to the subject.
  • the dosage for subcutaneous administration is generally 0.3-20, and preferably 0.3-3 mg/kg/day.
  • the present invention is useful in treating a mammal subject, such as humans, horses, and dogs.
  • the present invention is particularly useful in treating humans.
  • the structure of 4-methylsulfonyl-2-butenenitrile comprises 7 protons. All protons are accounted for and occur at reasonable chemical shifts. Chemical shift assignments for the methyl and methylene protons are unequivocal.
  • the two sets of multiplets between 6 ppm and 6.2 ppm can be distinguished by their coupling constants (J). J ⁇ 16 Hz is consistent with the coupling constant expected for alkene protons in an ⁇ -configuration, whereas J ⁇ l 1 Hz is consistent with the coupling constant expected for alkene protons in a Z-configuration.
  • the E/Z ratio is -58/42. Coupling constants for the remaining alkene protons cannot be measured exactly due to the complexity of the signals between 6.6 ppm and 7 ppm.
  • the spectrum contains some impurity/solvent peaks (RlVxotai 3.75).
  • Table 2 exemplifies one gel formulation containing 4-methylsulfonyl-2-butenenitrile.
  • test compound indomethacin (positive control)
  • vehicle vehicle were evaluated for anti-inflammatory activity in a topical arachidonic acid-induced ear swelling model in mice.
  • mice weighing 22 ⁇ 2 g were used and randomly divided; the test compound and vehicle control had 10 mice, and indomethacin had 5 mice.
  • Arachidonic Acid (0.5 mg in 20 ⁇ of acetone :ethano 1/1 : 1) was applied topically to the anterior and posterior surfaces of the right ear of each mouse. Test substances and vehicle, as listed in Table 2 were similarly applied 30 min before and 15 min after arachidonic acid application. The thickness of the right ear and the left ear was measured and the difference calculated as an indication of the inflammation in the right ear. Ear swelling was measured by a Dyer model micrometer gauge at 60 and 90 minutes after arachidonic acid application as an index of inflammation.
  • the active compound 4-methylsulfonyl-2-butenenitrile is dissolved in a vehicle (DMSO) to 5-15 mg/mL.
  • DMSO a vehicle
  • the test compound, dexamethasone (positive control), and vehicle are orally administered to mice and evaluated for anti-inflammatory activity in the topical arachidonic acid induced ear swelling model in mice.
  • mice Male ICR derived mice are used in this experiment. 10 mice are used for each group (active compound, positive control, and vehicle). All animals are maintained in a controlled temperature (22-24°C) and humidity (60% - 70%) environment with 12-hour light/dark cycles for at least one week prior to use.
  • Arachidonic acid (0.5 mg in 20 ⁇ acetone) is applied topically onto the anterior and posterior surfaces of the right ear of test animals to induce inflammation.
  • Test compound in vehicle (10 mL/kg) and vehicle (10 mL/kg, 50-1 0 mg/kg) are orally administered by gavage 1 hour before arachidonic acid, whereas dexamethasone is orally administered by gavage 3 hour before arachidonic acid challenge.
  • the thickness of the right ear and the left ear is measured and the difference calculated as an indication of the inflammation in the right ear.
  • Significant activity is defined as a statistically significant inhibition (p-value determined by t-test was ⁇ 0.05) in arachidonic acid induced ear swelling relative to the vehicle-treated group.
  • Formalin test is a model of continuous pain resulting from formalin-induced tissue injury. Nociceptive and inflammatory pain is induced by injection of a dilute formalin solution into the paw, resulting in nocifensive behavior including paw flinching.
  • the formalin model encompasses inflammatory, neurogenic, and central mechanism of pain. The early phase of pain (from 0 to about 10 minutes) is due to nociceptive mechanism and the late phase of pain (from 10-40 minutes) is due to a combination of inflammatory pain and nociceptive mechanism. Pain behavior is assessed using manual paw licking measurements. The endpoints of the study are the number of paw licking events. (Hunskaar et al., Pain, 30:103-114, 1987; Li ct ah, Molecular Pain, 6:11, 2010)
  • mice per group are used in the study. Immediately prior to testing (at time 0), mice are restrained in a cloth and injected with 20 ⁇ ⁇ of a 5% formalin solution,
  • Vehicle control (DMSO) and test compound 4-methylsulfonyl-2-butenenitrile (in DMSO) are administered by oral gavage with a volume of 5 mL/kg to mice.
  • the amounts of test compound are 100 or 500 mg/kg per dose.
  • Positive control morphine in saline is administered by subcutaneous injection at 8 mg kg to mice, immediately before formalin injection and testing at time zero.
  • mice The number of licking events at different time points post formalin injection of vehicle control, morphine-treated, and test compound-treated mice are plotted in 5 minute intervals.
  • the numbers of licking events per minute are calculated between 0-10 minutes and 10-40 minutes for vehicle, positive control, and test compound. A statistically significant reduction of licking event per minute is an indication that the test compound is effective in treating acute nociceptive pain (early phase) or inflammatory nociceptive pain (late phase).
  • Example 6 Analgesic Activity of Active Compound by Topical Administration in Mice (Formalin Model, Prophetic Example) The animals and the treatment protocol are similar to those described in Example 5, except the following.
  • Morphine is subcutaneous ly administered once 15 minutes before formalin injection.
  • the test compounds and vehicle control are topically administered twice (BID), at 60 minutes before formalin injection.
  • mice The number of licking events at different time points post formalin injection of vehicle control, morphine-treated, and test compound-treated mice are determined.
  • the numbers of licking events per minute are calculated between 0-10 minutes and 10-40 minutes for vehicle, positive control, and test compound.
  • a two-sample t-test is done to compare the vehicle group with the test compound group. Significance is set at P ⁇ 0.05 level.
  • Peripheral nerve lesions may generate a syndrome comprising, in addition to spontaneous pain, exaggerated responses to light touch (tactile allodynia).
  • Chronic constriction injury model is a neuropathic pain model.
  • Rats are pre-selected for experimentation only if the pain threshold 7-14 days after nerve ligation (pre-treatment) is reduced by 10 grams of force relative to the response of the individual paw before nerve ligation (pre-ligation), namely, with clear presence of allodynia.
  • the active compound 4-methylsulfonyl-2-butenenitrile is prepared in the gel formulation according to Example 2.
  • Active compound in gel formulation (1 or 5%, topical administration), active compound in DMSO (500 mg/kg, oral administration), morphine (positive control, subcutaneous, 8 mg/kg in saline), topical vehicle (gel formulation without the active compound), and oral vehicle (DMSO) are evaluated.
  • Test substance or vehicle is either administered orally or topically to the plantar surface of the left hind paw.
  • the mechanical allodynia test is performed 30 min before (pre- treatment) and 1 and 3 hours after a single dose of test substance or vehicle (post treatment). Paw withdraw thresholds of control and tested compound are measured.
  • Topical Formulation The gel formulations containing the active compound 4- methylsulfonyl-2-butenenitrile at 1% and 5% (Example 2) are used in this example. Placebo contains the same gel without the active compound.
  • Patients with painful osteoarthritis of the knee controlled by a stable dose of standard NSAID therapy for at least 2 months, discontinue use of the NSAIDs for a 7-day washout period. Patients are then randomized in a 1 : 1 : 1 ratio (1% active gel, 5% active gel, placebo). A total of up to 150 patients are enrolled.
  • the active gel or placebo is applied to the affected knee 3 times a day for 12 weeks for a total of 252 treatments given every 4 - 6 hours while awake.
  • NSAIDs may be restarted after the Week 12 visit.
  • the primary clinical activity parameters are the measurement of pain in the target joint, as quantified by the Visual Analog Scale (VAS) and the Western Ontario and
  • McMaster University (WOMAC) Index pain subscale The effect of treatment on swelling, tenderness and inflammation of the knee is recorded, also the time to reduction or eradication of pain after treatment is recorded.
  • the primary clinical activity endpoint is:
  • the secondary clinical activity endpoints are:
  • Example 9 Treatment of Knee Pain by Oral Administration (Prophetic Example) The design and protocols of this experiment are similar to those described in Example
  • Oral Formulation Tablet formulations containing 10, 100, or 1000 mg of the active compound 4-methylsulfonyl-2-butenenitrile are used in this example. Placebo has the same tablet formulation without the active compound.
  • Patients are then randomized in a 1 :1 :1 :1 ratio (10 mg: 100 mg: 1000 mg: placebo). A total of up to 200 patients are enrolled.
  • the active tablet or placebo is administered orally to each patient two times a day for

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Cette invention concerne un 4-méthylsulfonyl-2-butènenitrile, ou un sel pharmaceutiquement acceptable, un isomère ou des isomères de celui-ci. Cette invention concerne également une composition pharmaceutique comprenant un véhicule pharmarceutiquement acceptable et un 4-méthylsulfonyl-2-butènenitrile, ou un sel pharmaceutiquement acceptable, un isomère ou des isomères de celui-ci. Une méthode destinée à traiter l'inflammation, les troubles liés à l'inflammation, ou la douleur, par administration du 4-méthylsulfonyl-2-butènenitrile, ou d'un sel pharmaceutiquement acceptable ou solvate de celui-ci à un sujet en ayant besoin est en outre décrite.
EP14852179.2A 2013-10-07 2014-10-01 4-méthylsulfonyl-2-butènenitrile et son utilisation pharmaceutique Withdrawn EP3055286A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887776P 2013-10-07 2013-10-07
PCT/US2014/058685 WO2015054008A1 (fr) 2013-10-07 2014-10-01 4-méthylsulfonyl-2-butènenitrile et son utilisation pharmaceutique

Publications (2)

Publication Number Publication Date
EP3055286A1 true EP3055286A1 (fr) 2016-08-17
EP3055286A4 EP3055286A4 (fr) 2017-05-24

Family

ID=52813515

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14852179.2A Withdrawn EP3055286A4 (fr) 2013-10-07 2014-10-01 4-méthylsulfonyl-2-butènenitrile et son utilisation pharmaceutique

Country Status (4)

Country Link
EP (1) EP3055286A4 (fr)
JP (1) JP6426746B2 (fr)
CN (1) CN105683158A (fr)
WO (1) WO2015054008A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015094626A1 (fr) * 2013-12-20 2015-06-25 The Procter & Gamble Company Couche avec manchons et confort améliorés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3444175A (en) * 1966-11-09 1969-05-13 Merck & Co Inc Certain picolylmethyl sulfones
US8476316B2 (en) * 2010-12-15 2013-07-02 Olatec Industries Llc 3-methanesulfonylpropionitrile for treating inflammation and pain
KR102002664B1 (ko) * 2012-02-27 2019-07-23 오라텍 세라퓨틱스 엘엘씨 3-메틸술포닐프로피오니트릴의 제조 방법
WO2014043144A1 (fr) * 2012-09-11 2014-03-20 Olatec Industries Llc Méthodes de traitement de l'inflammation et de la douleur

Also Published As

Publication number Publication date
JP6426746B2 (ja) 2018-11-21
EP3055286A4 (fr) 2017-05-24
JP2016539179A (ja) 2016-12-15
CN105683158A (zh) 2016-06-15
WO2015054008A1 (fr) 2015-04-16

Similar Documents

Publication Publication Date Title
US20210059971A1 (en) Pharmaceutical composition for treating inflammation and pain
US10441555B2 (en) Pharmaceutical composition
US9750714B2 (en) Pharmaceutical use of 3, 4-bis-benzylsulfonylbutyronitrile
EP3048886B1 (fr) 3,4-bis-benzylsulfonylbutanenitrile et son utilisation pharmaceutique
US9114122B2 (en) Compounds for treating inflammation and pain
WO2014043144A1 (fr) Méthodes de traitement de l'inflammation et de la douleur
US9770429B2 (en) 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use
EP3055286A1 (fr) 4-méthylsulfonyl-2-butènenitrile et son utilisation pharmaceutique
AU2014308958B2 (en) Pharmaceutical composition and use of diethyl (2-cyanoethyl)phosphonate
EP3052475B1 (fr) Utilisation pharmaceutique du 3-benzylsulfonylpropionitrile
EP2861228B1 (fr) Composés destinés au traitement de l'inflammation et de la douleur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170426

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 317/44 20060101AFI20170420BHEP

Ipc: A61P 29/00 20060101ALI20170420BHEP

Ipc: A61K 31/275 20060101ALI20170420BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171123